# Lianchuan Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lianchuan-biotechnology

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.lc-bio.com
- Total disclosed funding: $41M
- Latest round: Series C (Oct 12, 2021)
- Investors on record: 8

## About

Established in 2006 and based in Hangzhou, China, Lianchuan Biotechnology is a gene capture core technology company that provides gene technology service and products. The company list on the New Third Board in April 2017 and unlisted in May 2020.

The company focuses on the research and development of VariantPro™ gene capture technology and provides tumor liquid biopsy detection kits. The company also provides cross-omics integrated analysis services based on its platform such as µParaflo® microfluidic chip platform, single cell capture sequencing platform. The company cooperates with Biolidics.

The funding in 2021 will help to accelerate the process of exploring the commercial application of DNA synthesis technology platforms.

## Funding rounds

- Series C, Oct 12, 2021, $16M — Sinowisdom, Haibang Venture, Jinju Capital, HY Energy Group
- Series B, Jun 28, 2020, $16M — Sinowisdom, Zheshang Venture Capital, Crestvalue, Heda Venture, Junchuan Capital
- Series A, Oct 10, 2017, $9.7M — Sinowisdom, Zheshang Venture Capital, Crestvalue
- Angel, Jul 10, 2016 — Zheshang Venture Capital

## Investors

- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Angel, Series A, Series B
- Sinowisdom (https://capitalatlas.ai/funds/sinowisdom) — Series A, Series B, Series C
- Crestvalue (https://capitalatlas.ai/funds/crestvalue) — Series A, Series B
- Heda Venture (https://capitalatlas.ai/funds/heda-venture) — Series B
- Junchuan Capital (https://capitalatlas.ai/funds/junchuan-capital) — Series B
- Haibang Venture — Series C
- Jinju Capital — Series C
- HY Energy Group — Series C